氯喹剂量与伯氨喹对间日疟复发的影响:世界抗疟耐药网络系统综述与个体患者汇总Meta分析
该研究通过系统综述与个体患者数据汇总Meta分析,纳入37项临床试验、5240例间日疟患者,发现氯喹剂量常低于目标25 mg/kg,氯喹剂量每增加5 mg/kg可降低复发风险(AHR 0.82),加用伯氨喹使第42天复发风险降至4.9%(AHR 0.10)。作者认为在未用伯氨喹时,将5岁以下儿童推荐剂量增至30 mg/kg可大幅减少早期复发。
要点
- 氯喹治疗间日疟常剂量不足,2990例单用氯喹者中1041例(34.8%)剂量低于目标25 mg/kg。
- 氯喹剂量每增加5 mg/kg,总体复发率降低(AHR 0.82,95%CI 0.69-0.97;p=0.021)。
- 加用伯氨喹使第42天复发风险降至4.9%,显著低于单用氯喹(AHR 0.10,95%CI 0.05-0.17;p<0.0001)。
核心结论
- 氯喹在间日疟治疗中常剂量不足;在未用伯氨喹时,将5岁以下儿童推荐剂量增至30 mg/kg可大幅降低早期复发风险。
- 伯氨喹根治对预防早期复发高度有效,并可能改善抗氯喹耐药间日疟的血液杀裂殖体疗效。
研究设计与样本
- 系统综述与个体患者数据汇总Meta分析,检索MEDLINE、Web of Science、Embase和Cochrane系统综述数据库,纳入2000年1月1日至2017年3月22日发表的间日疟临床试验。
- 共纳入37项研究(来自17个国家)、5240例患者;采用随机效应Cox回归分析研究氯喹剂量与伯氨喹使用对第7天至第42天复发率的作用。
- 研究方案注册于PROSPERO,编号CRD42016053310。
主要发现
- 2990例患者单用氯喹治疗,其中1041例(34.8%)接受低于目标25 mg/kg的剂量。
- 第42天复发风险为32.4%(95%CI 29.8-35.1)。
- 控制混杂因素后,氯喹剂量每增加5 mg/kg总体降低复发率(AHR 0.82,95%CI 0.69-0.97;p=0.021),在5岁以下儿童中亦降低(AHR 0.59,95%CI 0.41-0.86;p=0.0058)。
- 加用伯氨喹使第42天复发风险降至4.9%(95%CI 3.1-7.7),低于单用氯喹(AHR 0.10,95%CI 0.05-0.17;p<0.0001)。
关键数值与推荐
- 单用氯喹组第42天复发风险32.4%(95%CI 29.8-35.1)。
- 氯喹剂量每增加5 mg/kg的总体调整风险比AHR 0.82(95%CI 0.69-0.97;p=0.021)。
- 5岁以下儿童氯喹剂量每增加5 mg/kg的调整风险比AHR 0.59(95%CI 0.41-0.86;p=0.0058)。
- 加用伯氨喹组第42天复发风险4.9%(95%CI 3.1-7.7),与单用氯喹相比AHR 0.10(95%CI 0.05-0.17;p<0.0001)。
临床怎么用
- 作者认为,在未给予伯氨喹时,将5岁以下儿童氯喹推荐剂量增至30 mg/kg可大幅降低早期复发风险。
- 作者指出伯氨喹根治对预防早期复发高度有效,并可能改善抗氯喹耐药间日疟的血液杀裂殖体疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria despite increasing reports of treatment failure. We did a systematic review and meta-analysis to investigate the effect of chloroquine dose and the addition of primaquine on the risk of recurrent vivax malaria across different settings. METHODS: A systematic review done in MEDLINE, Web of Science, Embase, and Cochrane Database of Systematic Reviews identified P vivax clinical trials published between Jan 1, 2000, and March 22, 2017. Principal investigators were invited to share individual patient data, which were pooled using standardised methods. Cox regression analyses with random effects for study site were used to investigate the roles of chloroquine dose and primaquine use on rate of recurrence between day 7 and day 42 (primary outcome). The review protocol is registered in PROSPERO, number CRD42016053310. FINDINGS: Of 134 identified chloroquine studies, 37 studies (from 17 countries) and 5240 patients were included. 2990 patients were treated with chloroquine alone, of whom 1041 (34·8%) received a dose below the target 25 mg/kg. The risk of recurrence was 32·4% (95% CI 29·8-35·1) by day 42. After controlling for confounders, a 5 mg/kg higher chloroquine dose reduced the rate of recurrence overall (adjusted hazard ratio [AHR] 0·82, 95% CI 0·69-0·97; p=0·021) and in children younger than 5 years (0·59, 0·41-0·86; p=0·0058). Adding primaquine reduced the risk of recurrence to 4·9% (95% CI 3·1-7·7) by day 42, which is lower than with chloroquine alone (AHR 0·10, 0·05-0·17; p<0·0001). INTERPRETATION: Chloroquine is commonly under-dosed in the treatment of vivax malaria. Increasing the recommended dose to 30 mg/kg in children younger than 5 years could reduce substantially the risk of early recurrence when primaquine is not given. Radical cure with primaquine was highly effective in preventing early recurrence and may also improve blood schizontocidal efficacy against chloroquine-resistant P vivax. FUNDING: Wellcome Trust, Australian National Health and Medical Research Council, and Bill & Melinda Gates Foundation.
引用
- Commons RJ, Simpson JA, Thriemer K, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018. PMID: 30033231. doi:10.1016/S1473-3099(18)30348-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。